.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF04_Stavudine.Stavudine .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF04_Stavudine.Stavudine| name: | Stavudine |
| ATC code: | J05AF04 | route: | oral |
| n-compartments | 1 |
Stavudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) formerly used in combination antiretroviral therapy for the treatment of HIV infection. Due to significant long-term toxicities, including peripheral neuropathy and lipodystrophy, its clinical use has been largely discontinued and is not recommended in current HIV treatment guidelines.
Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.
Horton, CM, et al., & Anderson, R (1995). Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrobial agents and chemotherapy 39(10) 2309–2315. DOI:10.1128/AAC.39.10.2309 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8619587
Panhard, X, et al., & Mentré, F (2007). Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. European journal of clinical pharmacology 63(11) 1019–1029. DOI:10.1007/s00228-007-0337-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17694300
Kwara, A, et al., & Court, MH (2009). Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. Journal of clinical pharmacology 49(9) 1079–1090. DOI:10.1177/0091270009338482 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19628728